SCHEMBL4405430

SCHEMBL4405430

O=c1cc(-c2ccc(OCc3ccccc3)c(OCc3ccccc3)c2)oc2ccc(OCC3CO3)cc12

nearest known ligand 0.51

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CYP1A1 P04798 2/20 0.51
CYP1A2 P05177 2/20 0.51
L3MBTL1 Q9Y468 2/20 0.49
KDM4E B2RXH2 1/20 0.47
NPC1 O15118 1/20 0.47
ALDH1A1 P00352 1/20 0.47
MAPT P10636 1/20 0.47
RAB9A P51151 1/20 0.47
BCHE P06276 2/20 0.46
ACHE P22303 2/20 0.46
SIGMAR1 Q99720 9/20 0.46
PKM P14618 1/20 0.45
ABCB1 P08183 1/20 0.45
ABCG2 Q9UNQ0 1/20 0.45
CYP1B1 Q16678 1/20 0.44
MAOA P21397 1/20 0.44
MAOB P27338 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4408510 0.93 CYP1A1 (0.52) CYP1A1CYP1A2L3MBTL1NPC1RAB9A
SCHEMBL10486636 0.85 MAPT (0.63) KDM4ENPC1ALDH1A1MAPTRAB9A
SCHEMBL31387373 0.82 PLA2G2A (0.61) CYP1A1CYP1A2L3MBTL1KDM4ENPC1
SCHEMBL4404228 0.81 FYN (0.64) CYP1A1CYP1A2L3MBTL1KDM4ENPC1
SCHEMBL1483628 0.81 PRKDC (0.52) L3MBTL1NPC1MAPTRAB9AACHE
SCHEMBL1483630 0.81 PRKDC (0.52) L3MBTL1NPC1MAPTRAB9AACHE
SCHEMBL1483626 0.81 PRKDC (0.52) L3MBTL1NPC1MAPTRAB9AACHE
SCHEMBL31387496 0.81 CYP1A1 (0.62) CYP1A1CYP1A2L3MBTL1KDM4ENPC1
SCHEMBL31387371 0.80 GABRP (0.62) CYP1A1CYP1A2L3MBTL1KDM4EALDH1A1
SCHEMBL8730031 0.79 TDP1 (0.57) CYP1A2NPC1ALDH1A1MAPTRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1807408-B1 OXY SUBSTITUTED FLAVONES AS ANTIHYPERGLYCEMIC AND ANTIDYSLIPIDEMIC AGENTS COUNCIL SCIENT IND RES (IN) 2016-06-08 EP disclosed
US-7635779-B2 Oxy substituted flavones as antihyperglycemic and antidyslipidemic agents COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2009-12-22 US disclosed
EP-1807408-A1 OXY SUBSTITUTED FLAVONES AS ANTIHYPERGLYCEMIC AND ANTIDYSLIPIDEMIC AGENTS Council of Scientific and Industrial Research (IN) 2007-07-18 EP disclosed
US-20060178373-A1 Oxy substituted flavones as antihyperglycemic and antidyslipidemic agents COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2006-08-10 US disclosed
WO-2006040621-A1 OXY SUBSTITUTED FLAVONES AS ANTIHYPERGLYCEMIC AND ANTIDYSLIPIDEMIC AGENTS COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) 2006-04-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060178373-A1 Oxy substituted flavones as antihyperglycemic and antidyslipidemic agents GPR119, LIPC, SLC5A2 CYP1A1 584/4885CYP1A2 136/4885L3MBTL1 2239/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.